

Cellular and Gene Therapy

Clinical research using Cellular and Gene Therapy/Editing for malignant and non-malignant disorders has expanded with advances in technology. The complex nature of these type of trials requires a Contract Research Organization (CRO) partner who is well versed in the unique nuances of successfully and efficiently managing all steps of research using cell and gene therapies. Furthermore, a CRO that has experience in collaborating with other researchers and shares a common, future vision across all phases of clinical development is critical.

As a full service CRO engaged in global cell and gene therapy studies, Emmes' wide expertise in various cell types and therapies along with complications from cellular therapies provides a strong foundation for a partner to leverage.



Highlights:

For the past 25 years we have maintained strong relationships with leading investigators and institutions, enabling our team of clinical research professionals to become adept at designing and conducting complex clinical trials in cell and gene therapies.

- 20+ year relationships with the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute of the National Institutes of Health (NIH).
- Leadership role in the NIH-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - a collaboration between Emmes, The National Marrow Donor Program/Be the Match, and The Center for International Blood and Marrow Transplant Research (CIBMTR).
- Leader of the NHLBI-funded Cure Sickle Cell Initiative (CureSCi) Coordinating Center.
- Leader of the NHLBI-funded Production Assistance for Cellular Therapies (PACT) coordinating center.
- Numerous Biopharma collaborations leading to market approval

Key Data:

Built on a long history of helping advance the science of hematology and cell and gene therapies, we believe that true medical advancement depends on learning from past experience, collaborating with other researchers and sharing a common, future vision.

- 100+ published papers.
- 125+ Studies Phase I-III primarily focused on Hematology indications.
- Conducted several global Phase III clinical trials focusing on cellular therapy or the complications of cellular therapy.

For additional information on our Hematology Experience, please visit www.emmes.com/hematology